As Small Cell Lung Cancer Rates Drop, Understanding of Disease Increases

“The more things change, the more they stay the same” could be a tagline for small cell lung cancer (SCLC). In recent decades, the epidemiology of SCLC has shifted substantially, as have the understanding of the disease, screening options and the treatments available. The malignancy, however, remains both challenging and highly lethal.

Overall Survival Improves With Adjuvant Pembrolizumab in RCC

A third prespecified interim analysis of the KEYNOTE-564 trial has determined that adjuvant pembrolizumab after surgery was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery.